Table 2 Inclusion criteria
We include patients with all of the following criteria: | |
|---|---|
1) | Patients who have been made aware of the research purpose, interests, and disadvantages of the clinical trial before starting the examination - They understand this, and written informed consent is obtained. No substitution is allowed. |
2) | Patients who are diagnosed with diffuse-type tenosynovial giant cell tumor (pigmented chorionic synovitis) or unresectable localized tenosynovial giant cell tumor occurring in the knee joint or ankle by radiological and pathological findings |
3) | Patient with measurable lesion based on RECISTa v1.1 with at least one knee or ankle joint |
4) | Patients who keep joint space in the knee or ankle joint in standing X-ray imaging |
5) | Patients aged 20 years or older but less than 70 years old at the time of acquisition |
6) | In the case of a pregnant woman, a patient whose pregnancy test, to be conducted during the screening period, is negative |